Chairman of the Board

Mr. Mackie is Chairman of bioLytical™ Laboratories Inc. His career in business spans more than 20 years; providing leadership and expertise to a number of companies. Mr. Mackie is experienced in import/export, business-to-business transactions, corporate takeover and restructuring, and marketing strategy. He was co-founder and owner of one of the largest mobile communications companies in Western Canada. For more than 10 years he has successfully managed land and commercial real estate within an international portfolio. Born and raised in British Columbia, Mr. Mackie is actively involved in a number of charitable organizations as well as fund raising for community sports and youth educational programs. He is an active contributor to the INSTI™ Foundation both at home and abroad.

President, Director

Mr. Bligh is the chairman of Galt Partners based out of Chicago. He is the former founder, Chairman, and CEO of Inforte Corp., a NASDAQ publicly traded international sales and marketing services firm. Mr. Bligh is also the former CEO and a current board member of the leading children’s ice cream brand Dippin’ Dots. He is the author of “CRM Unplugged”, a book on reaching customers through more effective sales and marketing techniques. Mr. Bligh also serves on the Board of Directors for Safepole LLC, a durable medical equipment company, Calance Corporation, a healthcare information technology consulting company, and is on the Advisory Board for Neogenix Oncology, a cancer therapeutics and in-vitro diagnostics company. Mr. Bligh is a former Ernst and Young Entrepreneur of the Year Award.
 

Chief Science Officer

Dr. O’Shaughnessy was hired as founding director of the B.C. Centre for Excellence in HIV/AIDS in 1992. In 2001, he was appointed Vice President of Research and Tertiary Programs at Providence Health Care, and Assistant Dean of Research in the Faculty of Medicine at the University of British Columbia. Under his leadership, the Centre has developed into a national and world leader in HIV/AIDS treatment and research. Dr. O’Shaughnessy retired as Director of the Centre in October 2003, but continues to be an opinion leader in HIV and health care issues.

Chief Technical Officer

Mr. Galli has over 31 years experience in Canada coordinating diagnostic and research laboratories in the area of infectious diseases. He has been directly involved with the laboratory diagnosis and monitoring of HIV infection since 1987, and has served on numerous advisory boards and associations, most recently as President of the Canadian Association of HIV Clinical Laboratory Specialists. Mr. Galli is responsible for bioLytical™’s scientific and clinical affairs.

Chief Financial Officer

Mr. Nurthen is the former Chief Financial Officer of Inforte Corp, a NASDAQ publicly traded international sales and marketing services firm. He has over 10 years of financial operations experience including various finance roles at Platinum Technology International and Ford Motor Company. In addition, he possesses extensive background in merger and acquisition transactions, initial public offerings, and public company governance and compliance. Mr. Nurthen holds a MBA from the Kellogg School of Management at Northwestern University and also graduated with a BBA in Finance from the University of Notre Dame.

Controller

Mr. Bjornson is the Controller for bioLytical. In 1994, he received his Bachelor of Commerce (with distinction) from the University of Victoria, British Columbia. In 1995 he commenced his articles with Deloitte Touche Tohmatsu International where he was a member of the assurance and advisory services group working with clients ranging from retail industry to biotechnology. In 1998, he was admitted as a member of the Institute of Chartered Accountants of British Columbia and the Canadian Institute of Chartered Accountants. Prior to joining bioLytical™, Mr. Bjornson was Vice President of a Bermuda group of companies specializing in financial and risk management services. His experience is both international and diverse. All enquiries about bioLytical™’s investor relations or company structure can be forwarded to Mr. Bjornson using our contact form.

Vice President of Manufacturing

Mr. Day became Vice President of Manufacturing for Biolytical Laboratories in April 2009. He has extensive experience in Manufacturing, Validation and Quality Control / Assurance. His experience is based primarily in the Pharmaceutical / Biotech. arena, beginning at GSK in England where he was responsible for sterilization, microbiology, rapid technologies and new product introduction. He moved to Canada in 2004 to work within a team of professionals who successfully commissioned and validated a state-of-the-art manufacturing facility for Vancouver based biotech. company and simultaneously led the Microbiology Department. Mr. Day has audited manufacturing facilities and also represented Quality Departments through internal and external audits for Pharmaceutical and Biotech. organizations and is now leading Biolytical Laboratories’ production scale-up activities.

back to top